From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Tissue Regenix – a further nightmare for shareholders including (natch) Neil Woodford investors…

By Steve Moore | Monday 11 November 2019


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Last month I noted on Tissue Regenix (TRX), the nightmare continues for Neil Woodford investors! – that with the company updating “revenue for 2019 will be below current market consensus by approximately 15% to 20%, with a corresponding reduction in margin impacting EBITDA” and I noting the recent results showed it heavily loss-making with net cash down to £4.3 million and near the top of the shareholders list was Woodford Investment Management (before stock transfer as it goes to toast – the latest notification showing Link Fund Solutions with 19.98%)! Now “Update in relation to loan facility”

You must be a registered member to read this story
ShareProphets is reader-supported journalism

Join us for free and gain access to three articles per month

Or become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

HAT

H&T Group – now again a Buy

Time left: 05:24:45